ImmunityBio(IBRX)
Focus: ImmunityBio is a San Diego-based public biotech focused on cellular therapy and immuno-oncology, with 71 active job openings and a diversified pipeline across oncology indications. The company is pre-commercial with minimal revenue ($622K in FY2025) and operates as a development-stage company.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
70+8 this month
Growing — net +8 jobs in 30d
34 jobs added vs 26 removed. Steady team buildout.
Should You Work at ImmunityBio?
AI assessmentImmunityBio offers frontier cellular therapy exposure and public-market equity upside, but severe burn rate, early-stage pipeline, and recent legal/compliance issues make this a high-risk, high-reward play best suited to risk-tolerant candidates.
Why Work Here
- Strong pipeline depth with 30 active programs across oncology and cell therapy, including 4 Phase 3 trials offering real advancement potential
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$622K
Pipeline & Clinical Trials
rMBCG
NMIBCClinical Trials (1)
NCT06810141ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
N/AHelp build intelligence for ImmunityBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.